References
- Berger ML, Grainger D. Comparative effectiveness research: the view from a pharmaceutical company. Pharmacoeconomics 28(10), 915–922 (2010).
- Greenfield S. Comparative effectiveness and the future of clinical research in diabetes. Diabetes Care 36, 2146–2147 (2013).
- Mansley EC, Elbasha EH, Teutsch SM, Berger ML. The decision to conduct a head-to-head comparative trial: a game theoretic analysis. Med. Decis. Making 27(4), 364–379 (2007).
- Teutsch SM, Berger ML, Weinstein MC. Comparative effectiveness: asking the right questions, choosing the right method. Health Aff. (Millwood) 24(1), 128–132 (2005).
- Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ. Availability of comparative efficacy data at the time of drug approval in the united states. JAMA 305, 1786–1789 (2011).
- Wang A, Halbert RJ, Baerwaldt T, Nordyke RJ. US payer perspectives on evidence for formulary decision making. J. Oncol. Pract. 8, 22s–27s (2012).
- Teutsch SM, Berger ML. Evidence synthesis and evidence-based decision making: related, but distinct processes (editorial). Med. Decis. Making 25(5), 487–489 (2005).
- Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources. The ISPOR good research practices for retrospective database analysis task force report – part I. Value Health 12(8), 1044–1052 (2009).
- Dreyer N, Schneeweiss S, McNeil B et al. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am. J. Manag. Care 16(6), 467–471 (2010).
- Berger ML, Dreyer N, Anderson F, Towse A, Sedrakyan A, Normand SL. Prospective observational studies to assess comparative effectiveness: the ISPOR good practices task force report. Value Health 15, 217–230 (2012).
- Caro JJ, Briggs AH, Siebert U et al. Modeling good research practices-overview: A report of the ISPOR-SMDM modeling good research practices task force-1. Value Health 15, 796–803 (2012).
- Neumann P. Communicating and promoting comparative-effectiveness research findings. NEJM 369, 209–211 (2013).
- Berger ML. Accelerating the development of comparative effectiveness information: does Phase IIIb represent an opportunity? ISPOR Connect. 18(5), 5–6 (2012).
- Timble J, Fox S, Van Busum K, Schneider E. Five reasons that many comparative effectiveness studies fail to change patient care and clinical practice. Health Aff. 31, 2168–2175 (2012).
Websites
- National Institutes of Health – News & Events.www.nih.gov/news/health/jul2013/nih-22.htm ( Accessed 22 July 2013)
- International Society for Pharmacoeconomics and Outcomes Research, Comparative Effectiveness Research-Collaborative Initiative (CER-CI) Advancing Appropriate Use of Comparative Evidence to Improve Patient Health Outcomes. www.ispor.org/TaskForces/InterpretingORSforHCDecisionMakersTFx.asp( Accessed 24 July 2013)